CASI Pharmaceuticals, Inc. Nasdaq

CASI

KYG1933S1012

Pharmaceuticals

Delayed Nasdaq Other stock markets 02:56:47 17/07/2026 HKT			5-day change	1st Jan Change
0.1533 ^USD	+9.49%		+5.72%	-81.96%

06-02	CASI Pharmaceuticals, Inc. Announces Resignation of Barbara Krebs-Pohl as Director, Effective May 31, 2026	CI
05-15	CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Top Premarket Decliners

Published on 08/18/2025 at 07:58 pm HKT

MT Newswires

Add MarketScreener to your sources

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Add MarketScreener to your sources

Latest news about CASI Pharmaceuticals, Inc.

06-02	CASI Pharmaceuticals, Inc. Announces Resignation of Barbara Krebs-Pohl as Director, Effective May 31, 2026	CI
05-15	CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
05-15	CASI Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	CI
04-21	CASI Pharmaceuticals, Inc. announced that it has received $20 million in funding from ETP Global III Fund LP	CI
04-21	CASI Pharmaceuticals, Inc. Announces Termination of Dr. Alexander A. Zukiwski, MD as Global Chief Medical Officer, Effective April 20, 2026	CI
03-03	CASI Pharmaceuticals, Inc. Announces CEO Changes	CI
03-03	Casi Pharmaceuticals, Inc. Announces Resignation of Director David Cory, Effective March 31, 2026	CI

Chart CASI Pharmaceuticals, Inc.

Duration

Period

CASI: Dynamic Chart

CASI Pharmaceuticals Inc is a holding company principally engaged in developing and commercializing innovative therapeutics and pharmaceutical products. The Companyâ€™s main business is engaged in acquiring, developing and commercializing products that augment its hematology oncology, autoimmune and organ transplant rejection therapeutic area focus as well as other unmet medical need. The Companyâ€™s main products include EVOMELA (Melphalan for Injection), FOLOTYN (Pralatrexate), CNCT19, BI-1206, CB-5339, CID-103, Thiotepa and others. The Company mainly conducts its business in the domestic market.

Employees

Sector

Pharmaceuticals

More about the company